论文部分内容阅读
目的 :探讨CD4 4v6表达与胰腺癌增殖活性、淋巴结转移以及预后的关系。方法 :应用免疫组化LSAB法检测 47例胰腺癌组织中CD4 4v6和PCNA的表达。结果 :CD4 4v6阳性率为 5 7.4% (2 7/ 47) ,与胰腺癌组织学类型及分级无关 ;伴淋巴结转移者CD4 4v6阳性率 (81.0 % ,17/ 2 1)明显高于无淋巴结转移者 (38.5 % ,10 / 2 6 ) ,两者间有极显著性差异 (χ2 =8.5 8,P <0 .0 1) ;CD4 4v6阴性者术后 1年生存率为 30 .0 % (6 / 2 0 ) ,而阳性者为 3.7% (1/ 2 7) ,两者间有显著性差异 (χ2 =6 .2 8,P <0 .0 5 ) ;CD4 4v6阳性染色的胰腺癌组织PCNA标记率较阴性者高 (χ2 =4.6 3,P <0 .0 5 )。结论 :CD4 4v6在胰腺癌的增殖及转移过程中起重要作用 ,并可作为预测胰腺癌预后的生物学标志。
Objective : To investigate the relationship between CD4 4v6 expression and proliferative activity, lymph node metastasis and prognosis of pancreatic cancer. Methods : The expression of CD4 4v6 and PCNA in 47 cases of pancreatic cancer was detected by immunohistochemical LSAB method. Results: The positive rate of CD4 4v6 was 5 7.4% (2 7/47), which was not associated with the histological type and grade of pancreatic cancer. The positive rate of CD4 4v6 (81.0 %, 17/21) in lymph node metastasis was significantly higher than that without lymph node metastasis. Of the patients (38.5%, 10/26), there was a significant difference between the two (χ2=8.58, P<0.01); the 1-year survival rate of CD4 4v6-negative patients was 30.0 % (6 / 2 0 ), and the positive was 3.7% (1/27). There was a significant difference between the two (χ2 = 6.28, P < 0.05); CD4 4v6 positive staining of pancreatic cancer tissue PCNA The marker rate was higher than that of the negative (χ2 =4.63, P<0.05). Conclusion :CD4 4v6 plays an important role in the proliferation and metastasis of pancreatic cancer and can be used as a biological marker for predicting the prognosis of pancreatic cancer.